On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
The clinical efficacy of B cell depleting therapies (BCDT) highlights the pathogenic potential of B cells in inflammatory diseases such as RA. We have recently identified a pathogenic B cell subset that is enriched both in the joints of patients with RA and in the inflamed mucosa. We are currently exploring their antigen specificity, gene expression profile and their functional role in mucosal and joint inflammation.
——
Dr Dagmar Scheel-Toellner:
2015- Reader in Translational Inflammation Research. University of Birmingham.
2010-2015 Senior Research Fellow (HEFCE), University of Birmingham.
2010-2011 Arthritis Research UK Career Progression Fellow. University of Birmingham.
2004-2009 Arthritis Research UK Career Development Fellow, University of Birmingham.
2003 Fellow of the Higher Education Academy.
1994-2004 Postdoctoral Research Fellow, with Prof. Mike Salmon and Prof. Janet Lord. University of Birmingham.
1990-1994 PhD student at the Forschungszentrum Borstel, Germany. Advisor: Prof. Johannes Gerdes. PhD in Immunology awarded “summa cum laude”.
1989 BSc Pharmacy, registered pharmacist, Christian Albrechts Universität, Kiel, Germany.
